Showing 8931-8940 of 10114 results for "".
- New Day Cream, Gel Oil from Ceravehttps://practicaldermatology.com/news/new-day-cream-gel-oil-from-cerave/2458371/Cerave is expanding their Renewing product line. A new Cerave Skin Renewing Day Cream with Broad Spectrum SPF 30 sunscreen and Skin Renewing Gel Oil now join existing products in this line including Renewing Cream Serum and Renewing Night Cream.
- Game Change: The New Global Psoriasis Atlas to Accrue Worldwide PsO Datahttps://practicaldermatology.com/news/game-change-the-new-global-psoriasis-atlas-to-accrue-worldwide-pso-data/2458419/Three global health organizations are joining forces to launch the Global Psoriasis Atlas (GPA), the first-ever worldwide database on psoriasis. The GPA project comes in response to the 2016 World Health Organization (WHO) Global Report on
- Beauty Business to Go Green with New Master Class, Institutehttps://practicaldermatology.com/news/beauty-business-to-go-green-with-new-master-class-institute/2458421/The newly formed National Beauty Science Institute (NBSI) aims to promote sustainability, authenticity and green energy in the beauty business. The group will hold its first Master Class in April 2017 to educate students and consumers on the science and sustainability of beauty – a
- FDA Approves Humira Biosimilarhttps://practicaldermatology.com/news/fda-approves-humira-biosimilar/2458424/The U.S. Food and Drug Administration today approved Amjevita (adalimumab-atto) as a biosimilar to Humira (adalimumab) for multiple inflammatory diseases. Amjevita is approved for the following indications in adult patients: ·  
- Is Bigger Better? Group Practices Become the New Normhttps://practicaldermatology.com/news/group-practices-are-the-new-norm/2458438/Group physician practices are the new normal, and it seems that dermatologists were ahead of the consolidation curve, according to research in the September 2016 issue of Health Affairs. Researchers examined physician consolidation for both primary care provide
- FDA Approves Enbrel Biosimilarhttps://practicaldermatology.com/news/fda-approves-enbrel-biosimilar/2458451/The U.S. Food and Drug Administration (FDA) approved Erelzi for multiple inflammatory diseases. Erelzi is a biosimilar to Enbrel (etanercept), which was originally licensed in 1998. The move is no surprise given the unanimous backing of an FDA advisory arm last month. There are now
- FDA Cracks Down on Mercury in Anti-Aging Productshttps://practicaldermatology.com/news/fda-cracks-down-on-mercury-in-anti-aging-products/2458488/The U.S. Food and Drug Administration is re-issuing a warning about the dangers of mercury in skin creams, beauty and antiseptic soaps, and lotions. In the past few years, the FDA and state health officials
- FDA Greenlights First-Ever OTC Retinoidhttps://practicaldermatology.com/news/fda-greenlights-first-ever-otc-retinoid/2458507/The U.S. Food and Drug Administration (FDA) approved Differin Gel 0.1% (adapalene), a once-daily topical gel for the over-the-counter (OTC) treatment of acne in people 12 years of age and older. Differin Gel 0.1% is the first retinoid to be made available OTC for the
- Changes Afoot at Valeant Pharmaceuticalshttps://practicaldermatology.com/news/changes-afoot-at-valeant-pharmaceuticals/2458527/Amid reports that its Obagi Medical Products and Solta Medical units are on the block, Valeant Pharmaceuticals is assuring investors that the company is focused on the future and has plans to fix its dermatology unit. Valeant CEO Joseph Papa cite
- FDA Approves Juvéderm Volbella XC for Use in Lips and Perioral Rhytidshttps://practicaldermatology.com/news/fda-approves-juvderm-volbella-xc-for-use-in-lips-and-perioral-rhytids/2458546/Allergan plc, has received FDA approval to market Juvéderm Volbella XC for use in the lips for lip augmentation and for correction of perioral rhytids, commonly referred to as perioral lines, in adults over the age of 21. In clinical trials, Juvéderm Volbella XC was found to effecti